Syndicated report (>100 pages) with the overview and statistics of key innovation funding and coverage with evidence development schemes in seven European countries
Innovative payment schemes are an important part of the reimbursement landscape for medical technologies. Two key types of schemes are innovation funding (when payment is provided for innovation unconditionally) and coverage with evidence development (when either financing for a study or coverage with the obligation to perform the study is provided to medical technology).
MTRC has developed an in-depth overview of the innovative payment schemes, active in 2019 in seven European countries, including detailed statistics about the activity of the schemes. This report is built on the 2018 report, sponsored by the Med Tech Europe, but it includes a significant revision of several sections, update of all statistical information, and several completely new sections (G-BA Innovation Fund in Germany, New subsidy for promising care in the Netherlands, Article 51 of the Social Security Law in France).
This report complements the series of MTRC analytical reports in the field of reimbursement for medical technologies, including reports on HTA for medical technologies in 2018 and funding frameworks and decisions for medical technologies.
Innovative payment schemes from Austria, Belgium, England, France, Germany, the Netherlands and Switzerland are included
2 innovation funding and 15 coverage with evidence development schemes are reviewed
Only schemes related to medical technologies are included
Objective, description, inclusion criteria, applicant, stakeholders involved, clinical and economic evidence requirements, statistics about the scheme
Number and list of published decisions in the recent years or in 2017-2018
Austria: Provisional procedure codes for new diagnostic or therapeutic methods (NUB);
Belgium: Restricted Clinical Application for invasive medical devices and implants (Application Clinique Limité);
England: Innovation Technology Payment (ITP), Innovation and Technology Tariff (ITT), and Commissioning through Evaluation;
France: Hospital Program of Clinical Research (PHRC), Health Economic Research Program (PRME), Innovation Package (forfait innovation) and List of biological and anatomocytopathology innovative acts outside the nomenclature (RIHN), Article 51 of the Social Security Law;
Germany: New diagnostic or therapeutic methods (Neue Untersuchungs- und Behandlungsmethoden, NUB) and Government-co-sponsored studies according to the §137e of the German Social Code Book V, G-BA Innovation Fund;
Netherlands: Small-scale experiments for the introduction of innovations (Innovatie voor kleinschalige experimenten), conditional funding of medical technologies within Basic Health Insurance (Voorwaardelijke toelating tot het basispakket) and new subsidy scheme for promising care;
Switzerland: Provisional reimbursement of medical procedures (Leistungen in Evaluation).